| Description: |
Resmetirom (MGL-3196, VIA-3196, resmetirom) is a potentially first-in-class, liver-targeted, orally active, selective thyroid hormone receptor (THR)-β agonist with an EC50 value of 0.21 μM. Resmetirom avoids the activation of THR-α receptors that mediate thyroid hormone activity outside of the liver, including the heart and bone. Resmetirom avoids the activation of THR-α receptors that mediate extrahepatic (including cardiac and skeletal) thyroid hormone activity and can be used in studies of non-alcoholic steatohepatitis (NASH). |
| Stability and Solubility Advice: |
Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials and used within 1 month. Avoid repeated freeze and thaw cycles. Storage conditions for some special products should refer to their storage details. |
